In Depth

Featured article

Biotechs surf obesity drug wave to go beyond GLP-1RAs

Also in this section

The opioid crisis: Different delivery systems tackle treatment needs

Pharma readies for climate disasters amidst supply chain concerns

CRISPR pipeline accelerates after milestone Casgevy approval

The future of cell and gene therapy manufacturing

Amgen showcases exciting potential in the obesity space at JPM24

Q&A: Regulatory reform necessary to improve obesity drug access

Novo to buy Catalent: The backlash begins

02/23/2024 20:50:44
  • Home | Biotechs surf obesity drug wave to go beyond GLP-1RAs
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • Bio Image Systems
  • phasetwo
  • In Depth
  • Biotechs surf obesity drug wave to go beyond GLP-1RAs
  • The opioid crisis: Different delivery systems tackle treatment needs
  • Pharma readies for climate disasters amidst supply chain concerns
  • CRISPR pipeline accelerates after milestone Casgevy approval
  • The future of cell and gene therapy manufacturing
  • Amgen showcases exciting potential in the obesity space at JPM24
  • Q&A: Regulatory reform necessary to improve obesity drug access
  • Novo to buy Catalent: The backlash begins
  • Sponsored Supplements
  • BEA Technologies
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
02/22/2024 00:00:00